Interferon Beta (Betaseron) Safety and Efficacy in AIDS and Advanced ARC Patients on Reduced-Dose AZT Regimen

This is a study about the safety and efficacy of a drug called Betaseron, which is a type of interferon beta, in helping patients with AIDS and advanced AIDS related complex (ARC). These patients are also receiving a reduced dose of another drug called zidovudine, often referred to as AZT. The goal is to see if Betaseron can improve treatment for these patients, addressing the challenges faced in managing their condition. This research is important as it could potentially lead to better care for those affected by AIDS and ARC. The study is designed as a randomized, double-blind, placebo-controlled trial, meaning some participants will receive Betaseron while others will receive a placebo, and neither the participants nor the researchers will know who gets which. This helps ensure the results are unbiased. Participants will continue with their reduced-dose AZT regimen. The safety and effectiveness of Betaseron will be evaluated throughout the study, with careful monitoring for any potential side effects or benefits.